Familial Chylomicronemia Syndrome clinical trials at UCSF

• A Study of AKCEA-APOCIII-LRx Administered to Patients With Familial Chylomicronemia Syndrome (FCS)

  open to eligible people ages 18 years and up

  The purpose of the study is to evaluate the efficacy of AKCEA-APOCIII-LRx as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.

  San Francisco, California and other locations

Last updated: May 25, 2021